glp-1 agonists in development Receptor and Research to Treat Overeating and Substance Use Disorders Mapping the effectiveness and risks

The primary cause for alarm is thyroid C-cell hyperplasia, which has been the subject of FDA boxed warnings since a research conducted on rats showing dose-dependent C-cell tumors (Madsen et al

GLP-1 inhibits high-glucose-induced oxidative injury of vascular endothelial cells

The treat-to-target strategy allowed patients to start low and increase the dose only when weight loss stalled

All kidney injury cases were associated with severe dehydration from vomiting or diarrhea

We present clinical strategies for adverse event mitigation, monitoring recommendations, contraindications, and practical considerations for treatment discontinuation or switching

doi: 10.7150/IJBS.59965 32 HayrehSS